药品详细
Caspofungin(卡泊芬净)
化学结构式图
中文名
卡泊芬净
英文名
Caspofungin
分子式
C52H88N10O15
化学名
N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-10,12-dimethyltetradecanamide
分子量
Average: 1093.3131
Monoisotopic: 1092.643062196
Monoisotopic: 1092.643062196
CAS号
179463-17-3
ATC分类
J02A Antimycotics for Systemic Use
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
Caspofungin (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. Caspofungin is administered intravenously.
生产厂家
- Merck and co inc
封装厂家
- Cardinal Health
- Merck & Co.
- Oso Biopharmaceuticals Manufacturing LLC
参考
Synthesis Reference | Not Available |
General Reference |
|
剂型
规格
化合物类型
Type | small molecule |
Classes |
|
Substructures |
|
适应症
药理
Indication | For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies. |
Pharmacodynamics | Caspofungin is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1,3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to Caspofungin by Aspergillus species has not been studied. |
Mechanism of action | Caspofungin inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase. |
Absorption | 92% tissue distribution within 36-48 hours after intravenous infusion |
Volume of distribution | Not Available |
Protein binding | 97% |
Metabolism |
Metabolized slowly by hydrolysis and N-acetylation
|
Route of elimination | After single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine. |
Half life | 9-11 hours |
Clearance |
|
Toxicity | Side effects include rash, swelling, and nausea (rare) |
Affected organisms |
|
Pathways | Not Available |
理化性质
Properties | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
Drug | Interaction |
---|---|
Cyclosporine | Cyclosporine increases the effect and toxicity of caspofungin |
Rifampin | Decreased levels/effects of caspofungin |
Tacrolimus | Caspofungin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Caspofungin therapy is initiated, discontinued or altered. |
食物相互作用
Not Available